Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record.

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Open access
Schmitz, M, Temme, A, Senner, V, Ebner, R, Schwind, S, Stevanovic, S, Wehner, R, Schackert, G, Schackert, H K, Fussel, M, Bachmann, M, Rieber, E P, Weigle, B·2007·British Journal of Cancer

Abstract

Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but the number of such antigens is still very limited. SOX2 was identified by screening an expression database for transcripts that are overexpressed in malignant glioma, but display minimal expression in normal tissues. Expression of SOX2 mRNA was further investigated in tumour and normal tissues by real-time PCR. Compared to cDNA from pooled normal brain, SOX2 was overexpressed in almost all (9 out of 10) malignant glioma samples, whereas expression in other, non-malignant tissues was almost negligible. SOX2 protein expression in glioma cell lines and tumour tissues was verified by Western blot and immunofluorescence. Immunohistochemistry demonstrated SOX2 protein expression in all malignant glioma tissues investigated ranging from 6 to 66% stained tumour cells. Human leucocyte antigen-A(*)0201-restricted SOX2-derived peptides were tested for the activation of glioma-reactive CD8+ cytotoxic T lymphocytes (CTLs). Specific CTLs were raised against the peptide TLMKKDKYTL and were capable of lysing glioma cells. The abundant and glioma-restricted overexpression of SOX2 and the generation of SOX2-specific and tumour-reactive CTLs may recommend this antigen as target for T-cell-based immunotherapy of glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603696

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 207

Metadata

Authors
Schmitz, M., Temme, A., Senner, V, Ebner, R., Schwind, S., Stevanovic, S., Wehner, R., Schackert, G., Schackert, H. K., Fussel, M., Bachmann, M., Rieber, E. P., & Weigle, B.
Venue
British Journal of Cancer
Published
2007-03-20
Volume
96
Issue
8
Pages
1293-1301
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2011090802
Cited by
207
References
0
FWCI
5.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. https://app.cochat.ai/papers/10.1038/sj.bjc.6603696
The paper
Schmitz, M., Temme, A., Senner, V, Ebner, R., Schwind, S., Stevanovic, S., Wehner, R., Schackert, G., Schackert, H. K., Fussel, M., Bachmann, M., Rieber, E. P., & Weigle, B. (2007). Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.